Skip to main content

Caris Life Sciences, Inc. (CAI) Stock Analysis

Oversold Bounce setup

HoldVALUE-TRAP 1/5Moderate Confidence

Healthcare · Biotechnology

Hold if already holding. Not a fresh buy at $16.14, but acceptable to hold if already in. Reasons: Concentration risk — Product: MI Profile (84.4%); Negative momentum.

Caris Life Sciences provides comprehensive molecular profiling and precision medicine solutions focused on oncology, with its MI Profile platform (whole exome and transcriptome sequencing) accounting for 84.4% of 2025 revenue from over 1,000,000 sequenced cases. The company... Read more

$16.14+53.3% A.UpsideScore 6.4/10#13 of 157 Biotechnology
QualityF-score9 / 9FCF yield2.24%
Stop $15.24Target $24.76(analyst − 13%)A.R:R 3.5:1
Analyst target$28.46+76.3%13 analysts
$24.76our TP
$16.14price
$28.46mean
$38

Hold if already holding. Not a fresh buy at $16.14, but acceptable to hold if already in. Reasons: Concentration risk — Product: MI Profile (84.4%); Negative momentum. Chart setup: Oversold RSI 27, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. Score 6.4/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity 93d clear, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.

Val5.7Qual7.2Grw10.0Mom2.8Sent8.0Ins5.0Peer5.5Tech6.7Risk4.36.4OVERALL

Thesis

Rewards
High-quality business
Strong growth profile
Wide economic moat
Risks
Concentration risk — Product: MI Profile (84.4%)
Negative momentum
Below 200-day MA

Key Metrics

P/E (TTM)—
P/E (Fwd)44.0
Mkt Cap$4.6B
EV/EBITDA32.4
Profit Mgn3.7%
ROE28.4%
Rev Growth78.8%
Beta—
DividendNone
Rating analysts17

Quality Signals

Piotroski F9/9MoatWideCompounder✓

Options Flow

P/C0.62bullish
IV161%elevated
Max Pain$3-84.5% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductMI Profile84%
    10-K Item 1A: 'MI Profile, our tissue-based profiling solution, which accounted for 84.4% of our revenue for the year ended December 31, 2025'

Material Events(8-K, last 90d)

  • 2026-04-02Item 1.01MEDIUM
    Caris entered $400M initial term loan plus $300M delayed draw credit facility with Blue Owl Capital and Blackstone as lenders, effective April 1, 2026. Unconditionally guaranteed by certain subsidiaries. No reason cited for prior credit arrangement termination.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Vol Acceleration
1.0
Ma Position
1.5
Rsi
3.0
Volume
10.0
Capitulation risk (RSI 27, below 200MA)Volume distribution (falling OBV)Below 200-MA, MA slope flatVolume surge (4.2x avg) on selloff
GatesMomentum 2.8<4.5Death cross (50MA < 200MA)A.R:R 3.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.40EARNINGS PROXIMITY 93d clearSEMI CYCLE PEAK CLEAROversold BounceSuitability: Aggressive
RSI
27 · Oversold
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $15.71Resistance $22.16

Price Targets

$15
$25
A.Upside+53.4%
A.R:R3.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Momentum score 2.8/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-12 (93d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CAI stock a buy right now?

Hold if already holding. Not a fresh buy at $16.14, but acceptable to hold if already in. Reasons: Concentration risk — Product: MI Profile (84.4%); Negative momentum. Chart setup: Oversold RSI 27, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. Target $24.76 (+53.4%), stop $15.24 (−5.9%), A.R:R 3.5:1. Score 6.4/10, moderate confidence.

What is the CAI stock price target?

Take-profit target: $24.76 (+53.3% upside). Target $24.76 (+53.4%), stop $15.24 (−5.9%), A.R:R 3.5:1. Stop-loss: $15.24.

What are the risks of investing in CAI?

Concentration risk — Product: MI Profile (84.4%); Negative momentum; Below 200-day MA.

Is CAI overvalued or undervalued?

Caris Life Sciences, Inc. trades at a P/E of N/A (forward 44.0). TrendMatrix value score: 5.7/10. Verdict: Hold.

What do analysts say about CAI?

17 analysts cover CAI with a consensus score of 4.2/5. Average price target: $28.

What does Caris Life Sciences, Inc. do?Caris Life Sciences provides comprehensive molecular profiling and precision medicine solutions focused on oncology,...

Caris Life Sciences provides comprehensive molecular profiling and precision medicine solutions focused on oncology, with its MI Profile platform (whole exome and transcriptome sequencing) accounting for 84.4% of 2025 revenue from over 1,000,000 sequenced cases. The company serves oncologists, biopharma partners, and academic centers; Caris Assure and Caris Detect blood-based solutions are under commercialization.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · INCY (Incyte Corporation) · CPRX (Catalyst Pharmaceuticals, Inc.) · ONC (BeOne Medicines Ltd.) · HALO (Halozyme Therapeutics, Inc.)